Holdings
23
Concentrated
Top 10 weight
78%
Concentration
Active share
-
Style
Equity
100%
Asset allocation
Portfolio
-Sectors
7High-conviction bets
-Top sector wt.
0.0%Cash
Market-cap allocation
Large cap53%
Mid cap38%
Small cap9%
Asset allocation
Equity100%
Top holdings
21.3%
9.0%
8.9%
Cipla LimitedEQUITY
8.9%Laurus Labs LimitedEQUITY
6.4%Lupin LimitedEQUITY
6.4%5.2%
Aurobindo Pharma LimitedEQUITY
4.7%3.6%
3.5%
Biocon LimitedEQUITY
3.2%Mankind Pharma LimitedEQUITY
3.1%3.0%
2.6%
Gland Pharma LimitedEQUITY
2.2%2.0%
Wockhardt LimitedEQUITY
1.7%Ajanta Pharma LimitedEQUITY
1.6%Abbott India LimitedEQUITY
1.4%Piramal Pharma LimitedEQUITY
1.1%Triparty RepoCASH_EQUIVALENT
0.1%Net Current AssetsCASH_EQUIVALENT
0.0%Cash Margin - CCILCASH_EQUIVALENT
0.0%AI Smart summary
Pros
- Balanced across the metrics we track.
Cons
- Compact 23-stock portfolio - higher single-stock impact.
- High top-10 concentration (78%).
Auto-generated from fund metrics. Educational only - not investment advice.
Peer comparison
Other funds in this category.
No peers found in this category.
Sector exposure
Full industry / sector breakdown aggregated from the fund's holdings.
99.9%